Home > DARE Reviews > Breast conservation therapy for stage I...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews.

Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials

Review published: 2008.

Bibliographic details: Yang SH, Yang KH, Li YP, Zhang YC, He XD, Song AL, Tian JH, Jiang L, Bai ZG, He LF, Liu YL, Ma B.  Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Annals of Oncology 2008; 19(6): 1039-1044. [PubMed: 18187486]

Quality assessment

This review found that there were no differences between breast conservation therapy and mastectomy in overall survival and local regional recurrence of cancer in women diagnosed with stage I or stage II breast cancer; however, the data may have been subject to some bias. The review was generally well-conducted and the authors' conclusions are likely to be reliable. Full critical summary

Abstract

BACKGROUND: We carried out a meta-analysis to determine the effectiveness of breast conservation therapy (BCT) or mastectomy (MT) for stage I or stage II breast cancer.

METHODS: A fully recursive literature search was conducted in the Cochrane Controlled Trials Register Databases, Medline, EMBASE and Chinese Biomedical Literature Database in any language. Randomized controlled trials (RCTs) were considered for inclusion. Analyses were carried out using RevMan software.

RESULTS: In all, 18 RCTs including a total of 9388 patients were included. The meta-analysis showed that the overall survival in 3, 5, 10, 15 and 20 years and the locoregional recurrence rate in 3, 5, 15 and 20 years were not statistically significantly different between group BCT and group MT, but 10-year locoregional recurrence rate increased in group BCT. The sensitivity analysis indicated that both overall survival and locoregional recurrence rate were not statistically significant difference between group BCT and group MT. In the subgroup analysis, there was no significant difference in OS and locoregional recurrence rate between group BCT and group MT, but 20-year locoregional recurrence rate was statistically significantly higher in group BCT than group MT for women with tumors 2 cm or smaller.

CONCLUSION: BCT was better choice than MT for women with stage I or stage II breast cancer.

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2012 University of York.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...